Infusion immunotherapy through the liver artery for liver cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of immune “brakes” medicines (PD-1/PD-L1/CTLA-4) delivered through the liver’s artery, to help treat advanced liver cancer. It may help the immune system attack the cancer more effectively, especially if other local liver treatments aren’t possible or have stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed liver cancer (hepatocellular carcinoma) by biopsy or tissue testing.
- You can sign consent, are age 18–80, and you’re expected to live more than 3 months.
- Your liver function is “Child-Pugh A or B” (or score not too high) and your overall health/activity score is less than 2.
- Your blood counts and clotting, kidney function, and liver blood tests are within required ranges, checked within 7 days of treatment.
- You have at least one measurable tumor spot on scans and it cannot be treated with local procedures, or it has progressed after them.
- You must be able to have the liver-artery infusion safely and follow birth-control rules and clinic visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy drugs given directly into the liver’s blood supply as a first treatment for liver cancer. It aims to see if this approach can shrink tumors and improve outcomes for people with relatively preserved liver function.
This trial tests a combination of radiation therapy, an immunotherapy drug called camrelizumab, and a targeted therapy pill called apatinib for people with advanced liver cancer that has spread to the main blood vessel of the liver. The goal is to see if this triple therapy can shrink tumors and improve outcomes.
This trial tests a combination of two drugs (lenvatinib and toripalimab, a type of immunotherapy) plus a special chemotherapy infusion directly into the liver artery for people with advanced liver cancer that has not been treated before. The goal is to see if adding the immunotherapy helps shrink tumors better than the standard combination.
This trial compares an immune “checkpoint” medicine to a targeted cancer medicine in people with advanced liver cancer who have hepatitis B in the blood. It aims to lower hepatitis B surface antigen (HBsAg) levels and see which approach works better and is safest.
This trial tests a combination of two treatments—a targeted pill (donafenib) and an immunotherapy drug (pucotenlimab)—along with a type of chemotherapy given directly to the liver through a catheter. The goal is to see if this combination can shrink or control liver cancer better than standard options.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new Liver Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.